Skip to content

Price / book at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
2.6×+0.2×
Bausch + Lomb logo
Bausch + LombBLCO
0.9×+0.1×
HRO
HarrowHROW
45.7×+28.9×
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
8.6×+2.4×
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
20.8×+19.4×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
316.5×+303×

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Calculated from Ocular Therapeutix’s reported figures.

Based on the most recent quarter.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's price / book?
Ocular Therapeutix (OCUL) reported price / book of 3.2× in Q1 2026.
How has Ocular Therapeutix's price / book changed year-over-year?
Ocular Therapeutix's price / book decreased by 27.7% year-over-year, from 4.4× to 3.2×.
What is the long-term trend for Ocular Therapeutix's price / book?
Over 5 years (2020 to 2025), Ocular Therapeutix's price / book has grown at a -28.3% compound annual growth rate (CAGR), from 20.8× to 4×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.